Thursday, March 28, 2019 2:37:58 PM
We are a development stage company actively pursuing a business plan to develop, source and market high-quality pharmaceutical grade CBD products. Our new business plan, underway since our change of control in October 2018, has not yet generated any revenue or significant operations. We are currently preparing a study of the Chinese market for newly-developed CBD products, and of attractive global markets for a variety of established and newly-developed CBD products, and we intend to enter into contracts for the production of CBD products under our own private labels and market them in China and other attractive worldwide markets.
Recent SKYI News
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 12/15/2023 07:15:14 PM
- Form 10-12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 10/30/2023 02:57:22 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM